全文获取类型
收费全文 | 6881篇 |
免费 | 326篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 388篇 |
妇产科学 | 83篇 |
基础医学 | 829篇 |
口腔科学 | 156篇 |
临床医学 | 392篇 |
内科学 | 1439篇 |
皮肤病学 | 251篇 |
神经病学 | 305篇 |
特种医学 | 229篇 |
外科学 | 1016篇 |
综合类 | 470篇 |
一般理论 | 3篇 |
预防医学 | 369篇 |
眼科学 | 292篇 |
药学 | 396篇 |
1篇 | |
中国医学 | 33篇 |
肿瘤学 | 496篇 |
出版年
2023年 | 39篇 |
2022年 | 105篇 |
2021年 | 216篇 |
2020年 | 129篇 |
2019年 | 112篇 |
2018年 | 153篇 |
2017年 | 116篇 |
2016年 | 149篇 |
2015年 | 194篇 |
2014年 | 265篇 |
2013年 | 300篇 |
2012年 | 450篇 |
2011年 | 468篇 |
2010年 | 297篇 |
2009年 | 247篇 |
2008年 | 388篇 |
2007年 | 419篇 |
2006年 | 399篇 |
2005年 | 318篇 |
2004年 | 308篇 |
2003年 | 250篇 |
2002年 | 264篇 |
2001年 | 140篇 |
2000年 | 155篇 |
1999年 | 126篇 |
1998年 | 88篇 |
1997年 | 68篇 |
1996年 | 62篇 |
1995年 | 53篇 |
1994年 | 35篇 |
1993年 | 33篇 |
1992年 | 85篇 |
1991年 | 67篇 |
1990年 | 75篇 |
1989年 | 69篇 |
1988年 | 59篇 |
1987年 | 59篇 |
1986年 | 58篇 |
1985年 | 63篇 |
1984年 | 49篇 |
1983年 | 27篇 |
1982年 | 15篇 |
1981年 | 27篇 |
1980年 | 18篇 |
1979年 | 25篇 |
1978年 | 27篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 13篇 |
1971年 | 12篇 |
排序方式: 共有7229条查询结果,搜索用时 125 毫秒
81.
A massive change in the detection of psychiatric cases in the emergency room was recorded when pattern of coverage was changed from "on-call" basis to "continuous physical presence" of psychiatry residents in the emergency room. 相似文献
82.
Bhattacharya Salil K. Rao Patchala J. Mohan Bhattacharya Dipankar 《Pharmaceutical research》1984,1(5):229-231
Prostaglandin E1 (PGE1) produced dose-related catalepsy in rats when administered intracerebroventricularly. PGE1 induced catalepsy was significantly inhibited after pretreatment with pharmacological agents known to attenuate central serotonergic and cholinergic activity. It was also inhibited by PGF2 and naloxone. On the contrary, treatments enhancing central dopaminergic activity also reduced the cataleptic effect of PGE1. The results suggest that PGE1 induces catalepsy in rats by modulating activity of central neurotransmitters. 相似文献
83.
84.
85.
Carlos R Ferreira Dillon Kavanagh Ralf Oheim Kristin Zimmerman Julian Stürznickel Xiaofeng Li Paul Stabach R Luke Rettig Logan Calderone Colin MacKichan Aaron Wang Hunter A Hutchinson Tracy Nelson Steven M Tommasini Simon von Kroge Imke AK Fiedler Ethan R Lester Gilbert W Moeckel Björn Busse Thorsten Schinke Thomas O Carpenter Michael A Levine Mark C Horowitz Demetrios T Braddock 《Journal of bone and mineral research》2021,36(5):942-955
Inactivating mutations in human ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) may result in early-onset osteoporosis (EOOP) in haploinsufficiency and autosomal recessive hypophosphatemic rickets (ARHR2) in homozygous deficiency. ARHR2 patients are frequently treated with phosphate supplementation to ameliorate the rachitic phenotype, but elevating plasma phosphorus concentrations in ARHR2 patients may increase the risk of ectopic calcification without increasing bone mass. To assess the risks and efficacy of conventional ARHR2 therapy, we performed comprehensive evaluations of ARHR2 patients at two academic medical centers and compared their skeletal and renal phenotypes with ENPP1-deficient Enpp1asj/asj mice on an acceleration diet containing high phosphate treated with recombinant murine Enpp1-Fc. ARHR2 patients treated with conventional therapy demonstrated improvements in rickets, but all adults and one adolescent analyzed continued to exhibit low bone mineral density (BMD). In addition, conventional therapy was associated with the development of medullary nephrocalcinosis in half of the treated patients. Similar to Enpp1asj/asj mice on normal chow and to patients with mono- and biallelic ENPP1 mutations, 5-week-old Enpp1asj/asj mice on the high-phosphate diet exhibited lower trabecular bone mass, reduced cortical bone mass, and greater bone fragility. Treating the Enpp1asj/asj mice with recombinant Enpp1-Fc protein between weeks 2 and 5 normalized trabecular bone mass, normalized or improved bone biomechanical properties, and prevented the development of nephrocalcinosis and renal failure. The data suggest that conventional ARHR2 therapy does not address low BMD inherent in ENPP1 deficiency, and that ENPP1 enzyme replacement may be effective for correcting low bone mass in ARHR2 patients without increasing the risk of nephrocalcinosis. © 2021 American Society for Bone and Mineral Research (ASBMR). 相似文献
86.
Mohan Srivarshini Cherukupalli Walcott-Sapp Sarah Lee Minna K. Srour Marissa K. Kim Sungjin Amersi Farin F. Giuliano Armando E. Chung Alice P. 《Annals of surgical oncology》2021,28(11):5907-5917
Annals of Surgical Oncology - Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of... 相似文献
87.
Ashley D. Marumoto MD Srivarshini C. Mohan MD Stephanie A.K. Angarita MD Marissa K. Srour MD Vicky E. Norton Farnaz Dadmanesh MD Armando E. Giuliano MD 《The breast journal》2021,27(11):828-831
For women with breast cancer in whom multiple Oncotype DX® Recurrence Scores (RS) are obtained, RS concordance utilizing current NCCN recommendations has not been evaluated. Patients with two or more RS were identified. RS were stratified by NCCN guidelines and compared for concordance. Twenty-four patients were evaluated. RS concordance varied by tumor type: 100% in the same tumor, 91.7% in multiple ipsilateral tumors, 71.4% in contralateral tumors, and 66.7% in in-breast recurrent tumors. RS concordance for multiple assays in the same patient is not high enough to omit Oncotype DX® testing for each tumor. 相似文献
88.
Sudeshna Paul Taylor Melanson Sumit Mohan Katherine Ross-Driscoll Laura McPherson Raymond Lynch Denise Lo Stephen O. Pastan Rachel E. Patzer 《American journal of transplantation》2021,21(1):314-321
Kidney transplant program performance in the United States is commonly measured by posttransplant outcomes. Inclusion of pretransplant measures could provide a more comprehensive assessment of transplant program performance and necessary information for patient decision-making. In this study, we propose a new metric, the waitlisting rate, defined as the ratio of patients who are waitlisted in a center relative to the person-years referred for evaluation to a program. Furthermore, we standardize the waitlisting rate relative to the state average in Georgia, North Carolina, and South Carolina. The new metric was used as a proof-of-concept to assess transplant-program access compared to the existing transplant rate metric. The study cohorts were defined by linking 2017 United States Renal Data System (USRDS) data with transplant-program referral data from the Southeastern United States between January 1, 2012 and December 31, 2016. Waitlisting rate varied across the 9 Southeastern transplant programs, ranging from 10 to 22 events per 100 patient-years, whereas the program-specific waitlisting rate ratio ranged between 0.76 and 1.33. Program-specific waitlisting rate ratio was uncorrelated with the transplant rate ratio (r = −.15, 95% CI, −0.83 to 0.57). Findings warrant collection of national data on early transplant steps, such as referral, for a more comprehensive assessment of transplant program performance and pretransplant access. 相似文献
89.
90.